Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of “Moderate Buy” from Analysts

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been assigned an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, ten have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $46.50.

A number of equities analysts have recently issued reports on TYRA shares. Piper Sandler increased their price objective on shares of Tyra Biosciences from $42.00 to $56.00 and gave the company an “overweight” rating in a research note on Friday, March 20th. Canaccord Genuity Group started coverage on Tyra Biosciences in a research note on Monday, April 6th. They set a “buy” rating and a $50.00 price objective for the company. HC Wainwright raised their price target on shares of Tyra Biosciences from $30.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Guggenheim started coverage on shares of Tyra Biosciences in a research report on Tuesday, April 14th. They set a “buy” rating and a $54.00 target price for the company. Finally, Jefferies Financial Group upped their price target on Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, February 3rd.

Tyra Biosciences Stock Performance

Shares of NASDAQ:TYRA opened at $34.04 on Monday. The firm has a market cap of $2.03 billion, a PE ratio of -16.94 and a beta of 0.79. The firm’s 50 day simple moving average is $35.91 and its 200-day simple moving average is $27.61. Tyra Biosciences has a one year low of $8.75 and a one year high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03). Equities research analysts predict that Tyra Biosciences will post -2.42 EPS for the current fiscal year.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Gilla Kaplan sold 14,295 shares of the firm’s stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $36.97, for a total value of $528,486.15. Following the completion of the sale, the director owned 28,231 shares of the company’s stock, valued at approximately $1,043,700.07. This trade represents a 33.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TYRA. Commodore Capital LP grew its holdings in shares of Tyra Biosciences by 8.9% during the third quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock valued at $47,216,000 after buying an additional 275,000 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Tyra Biosciences by 2.1% in the 4th quarter. Janus Henderson Group PLC now owns 2,935,442 shares of the company’s stock valued at $77,085,000 after acquiring an additional 60,638 shares during the period. Farallon Capital Management LLC raised its stake in Tyra Biosciences by 80.7% in the 4th quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock worth $54,337,000 after acquiring an additional 923,000 shares during the last quarter. Vanguard Group Inc. raised its stake in Tyra Biosciences by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company’s stock worth $21,267,000 after acquiring an additional 118,492 shares during the last quarter. Finally, 5AM Venture Management LLC lifted its position in Tyra Biosciences by 9.6% during the 4th quarter. 5AM Venture Management LLC now owns 1,029,298 shares of the company’s stock worth $27,060,000 after acquiring an additional 90,000 shares during the period. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.